High-dose erythropoietin for tissue protection.

摘要: Background The discovery of potential anti-apoptotic and cytoprotective effects recombinant human erythropoietin (rHuEPO) has led to clinical trials investigating the use high-dose, short-term rHuEPO therapy for tissue protection in conditions such as stroke myocardial infarction. Experimental studies have been favourable, but efficacy yet be validated. Materials methods We reviewed regarding humans with purpose detail safety this indication. A systematic literature search was performed using PubMed/MEDLINE database randomized, placebo-controlled trials. Results Twenty-six randomized controlled that enrolled 3176 patients were included. The majority (20 including 2724 patients) reported no effect on measures protection. Five 1025 concerns form increased mortality or adverse event rates. No reduced mortality. Conclusions Evidence is sparse support a tissue-protective benefit humans. Moreover, number indicate administration high-dose associated an risk serious events. Further work needed elucidate mechanisms toxicity